ImmunoGen Inc (IMGN)

[skitahoe]

I believe we're just in the beginning of the growth in IMGN's share price. Besides news on wholly owned drugs, which begins with ASCO, but should involve many other conferences this year, we should get the conclusion of the registrational Phase 2 Trial being done by Bayer. A NDA from that trial could come late this year, or early next, so both milestones and sales royalties should be coming next year which should greatly enhance IMGN's financial position.

I believe that IMGN will end the year in double digit's, perhaps above the high achieved in 2015.

Gary